TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22717305

Group type: EXPERIMENTAL
Intervention: 5-hour preprocedural intravenous hydration with isotonic saline (5h-HS)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 20-hour preprocedural intravenous hydration with isotonic saline (20h-HS)
Number of subjects: 122
Study: 21129991

Group type: EXPERIMENTAL
Intervention: Biatrial reduction with reef‐imbricate suture technique and aggressive postoperative pharmacological therapy
Number of subjects: 322

Group type: COMPARATOR
Intervention: Maze procedure alone
Number of subjects: 322
Study: 20027097

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg intravenously)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 17474814

Group type: EXPERIMENTAL
Intervention: Atomoxetine 40 to 120 mg/day
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 15191378

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once-daily for 5-10 days
Number of subjects: 462

Group type: COMPARATOR
Intervention: Co-amoxiclav 500 mg + clavulanic acid 125 mg three-times-daily for 5-10 days
Number of subjects: 462
Study: 11159231

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 53
Study: 9491502

Group type: EXPERIMENTAL
Intervention: Two doses of a three-component acellular pertussis vaccine
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Three doses of a five-component acellular pertussis vaccine
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Three doses of a three-component acellular pertussis vaccine
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Two doses of a five-component acellular pertussis vaccine
Number of subjects: 248
Study: 8141107

Group type: COMPARATOR
Intervention: Ondansetron alone (O)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Ondansetron plus dexamethasone (OD)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Ondansetron plus dexamethasone plus lorazepam (ODA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Three-drug combination (ODA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Two-drug combination (OD)
Number of subjects: 75
Study: 3320274

Group type: EXPERIMENTAL
Intervention: 100% oxygen at 2 ATA for 90 minutes daily for 20 sessions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo therapy with air using a simulated compression procedure
Number of subjects: 120
Study: 30166311

Group type: EXPERIMENTAL
Intervention: Online cognitive behaviour therapy for insomnia (CBT-I)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Online patient education about sleep (PE)
Number of subjects: 1500
Study: 27072573

Group type: EXPERIMENTAL
Intervention: Online CBT with therapist telephone support
Number of subjects: 60

Group type: COMPARATOR
Intervention: Online CBT with no therapist
Number of subjects: 60
Study: 24830830

Group type: EXPERIMENTAL
Intervention: 6 g of fish oil
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 6 g of fish oil plus a multivitamin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 3 g of fish oil plus a multivitamin
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 6 g fish oil multivitamin combination
Number of subjects: 160
Study: 23453283

Group type: EXPERIMENTAL
Intervention: Unconditional Cash Transfers (UCT)
Number of subjects: 4043

Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfers (CCT)
Number of subjects: 4043

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4043
Study: 16148589

Group type: EXPERIMENTAL
Intervention: travoprost 0.004%/timolol 0.5% fixed combination
Number of subjects: 316

Group type: COMPARATOR
Intervention: Concomitant administration of travoprost 0.004% and timolol 0.5%
Number of subjects: 316
Study: 11991670

Group type: EXPERIMENTAL
Intervention: TGFbeta1 in human milk
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TGFbeta2 in human milk
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TGFbeta1 in plasma
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TGFbeta2 in plasma
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ratio of TGFbeta1 to TGFbeta2 in milk
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ratio of TGFbeta1 to TGFbeta2 in plasma
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Correlation between TGFbeta in milk and plasma
Number of subjects: 80
Study: 10049962

Group type: EXPERIMENTAL
Intervention: Once-daily dosing (ODD) of gentamicin at 4 mg/kg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Twice-daily dosing (TDD) of gentamicin at 2.5 mg/kg every 12 hours
Number of subjects: 55
Study: 7747292

Group type: EXPERIMENTAL
Intervention: New empirical antibiotic regimen
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (30 randomly chosen controls)
Number of subjects: 50
Study: 2040893

Group type: EXPERIMENTAL
Intervention: Agar dilution techniques
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Microbroth dilution techniques
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Agar methods with 64 micrograms/ml breakpoint
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Broth disk elution procedure
Number of subjects: 90
Study: 6785805

Group type: EXPERIMENTAL
Intervention: Chronic group received diazepam for 21 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acute group received diazepam at session 4
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group received placebo only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chronic group over sessions
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Withdrawal from chronic group
Number of subjects: 30
Study: 31793347

Group type: EXPERIMENTAL
Intervention: Collar-fitted stem
Number of subjects: 50

Group type: COMPARATOR
Intervention: Collarless stem
Number of subjects: 50
Study: 31621671

Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline placebo (nonsteroid group)
Number of subjects: 20
Study: 28244413

Group type: EXPERIMENTAL
Intervention: Earlier presentation of trial information at appointments (5 vs 3 for oligometastatic protocol, 4 vs 3 for NSCLC protocol, 3 vs 2 for esophageal protocol)
Number of subjects: 309
Study: 25203817

Group type: EXPERIMENTAL
Intervention: Low-volume sprint interval training (SIT) for 2 weeks (6 sessions of 4-6 maximal 30-s sprints)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Low-volume sprint interval training (SIT) for 5 weeks (1 SIT session/week)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Regular aerobic training (Control)
Number of subjects: 23
Study: 24060059

Group type: EXPERIMENTAL
Intervention: Responsive Classroom (RC) approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responsive Classroom (RC) practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21166852

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 18373615

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 28
Study: 16836554

Group type: EXPERIMENTAL
Intervention: T-shirt incentive
Number of subjects: 6919

Group type: EXPERIMENTAL
Intervention: Script A (patient story)
Number of subjects: 6919

Group type: COMPARATOR
Intervention: E-mail recruitment
Number of subjects: 6919
Study: 12780716

Group type: EXPERIMENTAL
Intervention: G. biloba extract 40 mg three times daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 11049008

Group type: EXPERIMENTAL
Intervention: tilidine/naloxone
Number of subjects: 12

Group type: COMPARATOR
Intervention: bromfenac
Number of subjects: 12
Study: 9493478

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venlafaxine IR
Number of subjects: 0
Study: 8404553

Group type: EXPERIMENTAL
Intervention: Bovie electrocautery technique
Number of subjects: 29

Group type: COMPARATOR
Intervention: Epinephrine-injection technique
Number of subjects: 29
Study: 3739817

Group type: EXPERIMENTAL
Intervention: Social Skills Training Group (SSTG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 24
Study: 30524137

Group type: EXPERIMENTAL
Intervention: Genetic inhibition of PCSK9
Number of subjects: 72385

Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 72385
Study: 27449641

Group type: EXPERIMENTAL
Intervention: Conventional treatment plus dexamethasone (20 mg iv from day 1 to day 5, and 10 mg iv from day 6 to day 10)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Conventional treatment without dexamethasone
Number of subjects: 314
Study: 25023370

Group type: EXPERIMENTAL
Intervention: Real rTMS of left DLPFC (+C/R)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sham rTMS of left DLPFC (+C/S)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham rTMS of left DLPFC (-C/S)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Real rTMS of left DLPFC (-C/R)
Number of subjects: 55
Study: 22704744

Group type: EXPERIMENTAL
Intervention: Graphic warning labels
Number of subjects: 200

Group type: COMPARATOR
Intervention: Text-only warning labels
Number of subjects: 200
Study: 20222964

Group type: EXPERIMENTAL
Intervention: Outpatient treatment feasibility as perceived by physicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient treatment feasibility as perceived by nurses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient treatment feasibility as perceived by patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient treatment feasibility as perceived by relatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of earlier discharge feasibility by physicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of earlier discharge feasibility by nurses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of earlier discharge feasibility by patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of earlier discharge feasibility by relatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reasons for inpatient management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptions across LRTI subgroups
Number of subjects: 0
Study: 18038273

Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 16152821

Group type: EXPERIMENTAL
Intervention: Qingxin Capsule (QC)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: AT1R AC plus CC gene type in EH patients
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: C allele distribution
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: AA gene type vs AA plus CC gene type
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Gene type and TCM syndrome type
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Gene type and hypotensive effect of treatments
Number of subjects: 206
Study: 12505568

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: rosuvastatin 80 mg
Number of subjects: 374

Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 374

Group type: COMPARATOR
Intervention: atorvastatin 80 mg
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 374
Study: 11008854

Group type: EXPERIMENTAL
Intervention: Two treatments focused on improving interpersonal relationships with social skills training
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Two treatments focused on improving interpersonal relationships without social skills training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 68
Study: 8880291

Group type: EXPERIMENTAL
Intervention: Clarithromycin (250 mg twice a day for 5 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once a day for 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 12
Study: 2050329

Group type: EXPERIMENTAL
Intervention: Torasemide (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furosemide (25 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 6630285

Group type: COMPARATOR
Intervention: Doxorubicin only (60 mg/m2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2) with tocopherol (200 mg i.m. 6 h before treatment) and nifedipine (60 mg p.o. daily from 2 days before infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined tocopherol and nifedipine pretreatment
Number of subjects: 12
Study: 31805483

Group type: EXPERIMENTAL
Intervention: Fluoride varnish containing NaF 22,500 ppm
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Toothpaste containing NaF 900 ppm and casein phosphopeptide-amorphous calcium phosphate fluoride (CPP-ACPF)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Desensitising cream containing NaF 9,000 ppm associated with 20% nanohydroxyapatite
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Toothpaste with NaF 5,000 ppm associated to tricalcium phosphate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Milli-Q water (Control)
Number of subjects: 50
Study: 30658483

Group type: EXPERIMENTAL
Intervention: Vitamin D (3200 IU daily for 3 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (daily for 3 months)
Number of subjects: 40
Study: 29308517

Group type: EXPERIMENTAL
Intervention: Raypex5 group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: i-root group
Number of subjects: 90

Group type: COMPARATOR
Intervention: X-ray group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Molar teeth
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Premolar teeth
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Front teeth
Number of subjects: 90
Study: 25733459

Group type: EXPERIMENTAL
Intervention: High-protein breakfast (35% protein/45% carbohydrate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-carbohydrate breakfast (15% protein/65% carbohydrate)
Number of subjects: 12
Study: 24152185

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Duloxetine plus gabapentin
Number of subjects: 407

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 407
Study: 23091134

Group type: EXPERIMENTAL
Intervention: 75% contaminated corn
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: 100% contaminated corn
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Contaminated corn (increased percentage)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: More than 50% contaminated corn
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: AFB(1) and AFB(2) contaminated groups
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Contaminated corn (increased concentration)
Number of subjects: 1200
Study: 19650424

Group type: EXPERIMENTAL
Intervention: Dosed submaximal physical exercise
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dosed maximal physical exercise
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (normal physical activity)
Number of subjects: 61
Study: 17391816

Group type: EXPERIMENTAL
Intervention: 1 ml dose of 7-valent pneumococcal conjugate vaccine
Number of subjects: 220

Group type: COMPARATOR
Intervention: 0.5 ml dose of 23-valent pneumococcal polysaccharide vaccine
Number of subjects: 220
Study: 15379756

Group type: EXPERIMENTAL
Intervention: Training (26 weeks; combined strength and endurance exercises, four sessions/week: two supervised and two at home)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Training (26 weeks)
Number of subjects: 29
Study: 11255811

Group type: EXPERIMENTAL
Intervention: 800 micrograms dry misoprostol
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: 600 micrograms wet misoprostol
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: 800 micrograms wet misoprostol
Number of subjects: 430
Study: 10220541

Group type: EXPERIMENTAL
Intervention: Beta blocker treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta blocker treatment in high risk patients requiring diuretics
Number of subjects: 0
Study: 8907622

Group type: EXPERIMENTAL
Intervention: Chloraminophene capsules
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chloraminophene tablets
Number of subjects: 12
Study: 2528718

Group type: EXPERIMENTAL
Intervention: Variable-practice group (100 trials from four different practice locations)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Specific-practice group (100 trials from the test-target location)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (unrelated kicking activity)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Variable-practice group
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Specific-practice group
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 941927

Group type: EXPERIMENTAL
Intervention: Regular grades
Number of subjects: 0

Group type: COMPARATOR
Intervention: Special classes
Number of subjects: 0
Study: 30176835

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) as add-on to antidepressant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo as add-on to antidepressant treatment
Number of subjects: 0
Study: 27012420

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU/d all rac-α-tocopheryl acetate)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Combined vitamin E and selenium (200 µg/d L-selenomethionine)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Selenium alone (200 µg/d L-selenomethionine)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 24938627

Group type: EXPERIMENTAL
Intervention: AF symptom severity (measured by Toronto AF Severity Scale)
Number of subjects: 558
Study: 22023436

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (12-week duration)
Number of subjects: 38
Study: 20398269

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate injections
Number of subjects: 120

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 120
Study: 18548482

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 15920042

Group type: EXPERIMENTAL
Intervention: Group 11-20 (17.1 +/- 0.4 METs per hour per week)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Group 21-30 (27.0 +/- 0.5 METs per hour per week)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Group 31-40 (37.5 +/- 0.5 METs per hour per week)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Group >40 (58.3 +/- 1.8 METs per hour per week)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Group 0 (no activity)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Group 1-10 (6.8 +/- 0.3 METs per hour per week)
Number of subjects: 179
Study: 11195741

Group type: EXPERIMENTAL
Intervention: Pterygium surgery
Number of subjects: 27
Study: 9771495

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression scale (HAD) at cut-off of 9/10
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: MOS mental health scale at cut-off score of 67/68
Number of subjects: 136
Study: 7530883

Group type: EXPERIMENTAL
Intervention: Abbott TestPack Strep A Plus
Number of subjects: 1389

Group type: EXPERIMENTAL
Intervention: Concise Strep A
Number of subjects: 1389

Group type: EXPERIMENTAL
Intervention: Kodak SureCell Strep A
Number of subjects: 1389
Study: 3203706

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Concomitant treatment with 10 mg benazepril and 40 mg furosemide
Number of subjects: 12

Group type: COMPARATOR
Intervention: 10 mg benazepril
Number of subjects: 12
Study: 2407810

Group type: COMPARATOR
Intervention: Fluorouracil (FUra) administered intravenously at a dose of 370 mg/m2/d for 5 days
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FUra) plus high-dose continuous infusion leucovorin calcium (500 mg/m2/d)
Number of subjects: 79
Study: 971163

Group type: EXPERIMENTAL
Intervention: Two 8‐h retardations in time (Westerly flight)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mepiprazole hydrochloride (therapeutic preparation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no time zone changes)
Number of subjects: 16
Study: 31929401

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo ring
Number of subjects: 96
Study: 31479152

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 51
Study: 28647745

Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline delivered via high aerosol output nebulizer
Number of subjects: 61

Group type: COMPARATOR
Intervention: 3% hypertonic saline delivered via low aerosol output nebulizers (large or small particles)
Number of subjects: 61
Study: 25826125

Group type: EXPERIMENTAL
Intervention: Hypoxic exercise training (HET; 15% O2, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normoxic exercise training (NET; 21% O2, n=20)
Number of subjects: 40
Study: 23772330

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) with preservation of the maxillary sinus ostium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) with enlargement of the maxillary sinus ostium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncinectomy only
Number of subjects: 30

Group type: COMPARATOR
Intervention: Middle meatal antrostomy
Number of subjects: 30
Study: 21161651

Group type: EXPERIMENTAL
Intervention: Cystone® (2 tablets BID for 1 year)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cystone® (12 weeks crossover study)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cystone® (1 year open label study)
Number of subjects: 10